科视视光品牌怎么样 申请店铺

我要投票 科视视光在个人护理行业中的票数:360 更新时间:2025-08-18
科视视光是哪个国家的品牌?「科视视光」是 郑州市科视视光技术有限公司 旗下著名品牌。该品牌发源于河南省郑州市,由创始人裴 *在1998年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力科视视光品牌出海!将品牌入驻外推网,定制科视视光品牌推广信息,可以显著提高科视视光产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

科视视光怎么样

科视视光技术有限公司是专业经营全球视光科技产品的大型连锁视光中心,一直专注于青少年及成人近视的预防与矫正,始终坚持与医疗单位合作,与全球眼科专家联动,为中国近视患者提供完善、科学的帮助与服务。

现已拥有上海科视、济南科视、海南科视、郑州科视、天津科视等16家科视直营店,数千家合作视光机构,服务网络覆盖上海、天津、河南、山东、浙江、海南等全国近80个地市,目前为全中国专业的角膜塑形镜验配中心。

科视视光总裁——裴兰是亚太地区青少年近视防控与矫正事业特殊贡献者,中国角膜塑形领域内专家,中国眼视光领域专家。拼搏源自使命,创新成就梦想,她必将继续带领科视中国,锐意前行,开创新的锦绣华章。

多年来,公司一直追求按照现代企业制度要求规范化运作,严格内部管理、锐化管理技能,始终坚持“以技术求生存,以管理求效益,以服务求发展”的战略指导思想,取得了较快发展。公司凭借行业内人才和技术精英的优势,大力打造效率、响应的运作团队,专注服务于广大近视患者,并力争成为角膜塑形镜行业内具竞争优势的企业。

科视视光技术有限公司凭借严格的品质管理、精湛的研发技术、稳定的生产工艺,完善的服务体系,给客户提供具有性价比的产品。在行业内已经形成相当规模,并使公司成为“产业化、规模化、标准化、程序化、制度化”的企业,从而使客户能真正实现“买的安心、用的放心”。

经过18年的风风雨雨,逐步发展壮大,以 “预防为主,矫正同步,减少发生,控制发展”为宗旨,科视视光寒暑不懈地对每一位加入防控系统的中小学生进行多方位、全时段的视觉健康监控与跟踪服务,已经帮助数十万近视青少年儿童成功摘镜。


Keshi optometry Technology Co., Ltd. is a large-scale chain optometry center specializing in the global optometry technology products. It has been focusing on the prevention and correction of juvenile and adult myopia. It has always insisted on cooperation with medical units and linkage with global ophthalmologists to provide perfect and scientific help and services for Chinese myopia patients. At present, it has 16 branch stores, including Shanghai Branch, Jinan Branch, Hainan Branch, Zhengzhou branch and Tianjin Branch, and thousands of cooperative optometry institutions. Its service network covers nearly 80 cities in China, including Shanghai, Tianjin, Henan, Shandong, Zhejiang and Hainan. At present, it is a professional keratology fitting center in China. Pei LAN, President of optometry, is a special contributor to the prevention, control and correction of juvenile myopia in the Asia Pacific region, an expert in the field of cornea shaping in China, and an expert in the field of optometry in China. Hard work comes from mission and innovation makes dreams come true. She will continue to lead science and Technology China to forge ahead and create a splendid chapter of innovation. Over the years, the company has been pursuing standardized operation in accordance with the requirements of modern enterprise system, strict internal management and sharpened management skills, and has always adhered to the strategic guiding ideology of "technology for survival, management for efficiency, service for development", and achieved rapid development. With the advantages of talents and technical elites in the industry, the company strives to build an efficient and responsive operation team, focus on serving the majority of myopia patients, and strive to become a competitive enterprise in the corneal plastic mirror industry. With strict quality management, exquisite R & D technology, stable production technology and perfect service system, Koshi opto Technology Co., Ltd. provides customers with cost-effective products. It has formed a considerable scale in the industry, and makes the company become an enterprise of "industrialization, scale, standardization, procedure, and institutionalization", so that customers can truly realize "buy safely, use safely". After 18 years of ups and downs, it has gradually developed and expanded. With the purpose of "prevention first, correction synchronous, reduction of occurrence, control of development", science and technology vision has been unremitting in providing all-round and full-time visual health monitoring and tracking services to every primary and secondary school student who has joined in the prevention and control system. It has helped hundreds of thousands of short-sighted children to successfully remove their mirrors.

本文链接: https://brand.waitui.com/520a3d206.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

东方生物:公司及子公司取得多项医疗器械注册证

36氪获悉,东方生物公告,公司及全资子公司美国衡健、上海万子健生物近日取得多项医疗器械注册证。境内注册证包括甲型/乙型流感病毒抗原检测试剂盒(胶体金法)(专业)和抗髓过氧化物酶抗体、抗蛋白酶3抗体、抗肾小球基底膜抗体检测试剂盒(流式荧光发光法)。境外注册证包括Healgen® Immunofluorescence Analyzer(OG-H180)和Healgen® AccuFluor Fentanyl Fluorescence Immunoassay(FIA) Test Kit-Qualitative。这些注册证的取得将丰富公司产品种类,提高市场竞争力,但实际销售业绩尚无法预测。

2小时前

ChatGPT移动应用已创造20亿美元收入

近日,应用情报提供商Appfigures的最新分析显示,自2023年5月推出以来,ChatGPT的iOS和Android应用在全球的收入已达到20亿美元。分析显示,这一数字约为ChatGPT竞争对手(包括Claude、Copilot和Grok)在移动端总收入的30 倍。数据显示,今年迄今为止,ChatGPT的移动应用已实现收入13.5亿美元,较2024年同期(1月至7月)的1.74亿美元同比增长673%。该应用平均每月营收接近1.93亿美元,高于去年的2500万美元。(财联社)

2小时前

天普股份:实际控制人筹划控制权变更事项,股票继续停牌

36氪获悉,天普股份公告,公司实际控制人尤建义正在筹划重大事项,该事项可能导致公司控制权发生变更。公司股票已于2025年8月15日停牌,预计无法在8月19日复牌,将继续停牌不超过3个交易日。

2小时前

金融街:上半年归母净利润亏损10.08亿元,同比亏损收窄

36氪获悉,金融街发布半年报。报告显示,公司上半年实现营业收入46.55亿元,同比下降51.79%;归属于上市公司股东的净利润亏损10.08亿元,上年同期亏损19.84亿元;基本每股收益-0.34元。

2小时前

辐照加速器小型化项目获千万级天使轮融资

36氪获悉,近日,“福照人间”于2025年7月顺利完成天使轮融资,投资方为上海普科拓朴私募基金管理有限公司,投资金额近千万元。资金将主要用于辐照加速器小型化的设备研发、创新工艺研究等领域。

2小时前

本页详细列出关于科视视光的品牌信息,含品牌所属公司介绍,科视视光所处行业的品牌地位及优势。
咨询